1
|
Wang B, Xu XJ, Fu Y, Ren B, Yang XD, Yang HY. A tumor-targeted and enzyme-responsive gold nanorod-based nanoplatform with facilitated endo-lysosomal escape for synergetic photothermal therapy and protein therapy. Dalton Trans 2024; 53:2120-2130. [PMID: 38180436 DOI: 10.1039/d3dt03305h] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2024]
Abstract
To tackle the obstacles related to tumor targeting and overcome the limitations of single treatment models, we have developed a nanoplatform that is both tumor-targeted and enzyme-responsive. This nanoplatform integrates photothermal gold nanorods (AuNRs) and protein drugs into a single system. This nanosystem, known as AuNRs@HA-mPEG-Deta-LA, was fabricated by modifying gold nanorods (AuNRs) with a polymeric ligand called hyaluronic acid-grafted-(mPEG/diethylenetriamine-conjugated-lipoic acid). The purpose of this fabrication was to load cytochrome c (CC) and utilize it for the synergetic protein-photothermal therapy of cancer. The resulting nanoplatform exhibited a high efficiency in loading proteins and demonstrated excellent stability in different biological environments. Additionally, CC-loaded AuNRs@HA-mPEG-Deta-LA not only enabled localized hyperthermia for photothermal therapy (PTT) with laser irradiation but also facilitated the release of CC under the action of hyaluronidase, an enzyme known to be overexpressed in tumor cells. The confocal imaging results demonstrated that the presence of a specific polymeric ligand on this nanoparticle enhances the internalization of CD44-positive cancer cells, accelerates endo/lysosomal escape, and facilitates the controlled release of CC within the cells. Furthermore, the results of the MTT assay also showed that AuNRs@HA-mPEG-Deta-LA as a protein nanocarrier demonstrated excellent biocompatibility. Importantly, this synergistic therapeutic strategy effectively induced apoptosis in A549 cancer cells by increasing the intracellular concentration of CC and utilizing the photothermal conversion of AuNRs, which was observed to be more effective compared to using only protein therapy or PTT. Therefore, this study showcased a nanoplatform based on AuNRs that has great potential for tumor-targeted protein delivery in combination with PTT in cancer treatment.
Collapse
Affiliation(s)
- Bo Wang
- Jilin Provincial Key Laboratory of Straw-Based Functional Materials, Institute for Interdisciplinary Biomass Functional Materials Studies, Jilin Engineering Normal University, Changchun 130052, P. R. China.
| | - Xin Jun Xu
- College of Materials Science and Engineering, Jilin Institute of Chemical Technology, Jilin City 132022, Jilin Province, China.
| | - Yan Fu
- College of Materials Science and Engineering, Jilin Institute of Chemical Technology, Jilin City 132022, Jilin Province, China.
| | - Bo Ren
- Jilin Provincial Key Laboratory of Straw-Based Functional Materials, Institute for Interdisciplinary Biomass Functional Materials Studies, Jilin Engineering Normal University, Changchun 130052, P. R. China.
| | - Xiao Dong Yang
- Jilin Provincial Key Laboratory of Straw-Based Functional Materials, Institute for Interdisciplinary Biomass Functional Materials Studies, Jilin Engineering Normal University, Changchun 130052, P. R. China.
| | - Hong Yu Yang
- College of Materials Science and Engineering, Jilin Institute of Chemical Technology, Jilin City 132022, Jilin Province, China.
| |
Collapse
|
2
|
Shi M, McHugh KJ. Strategies for overcoming protein and peptide instability in biodegradable drug delivery systems. Adv Drug Deliv Rev 2023; 199:114904. [PMID: 37263542 PMCID: PMC10526705 DOI: 10.1016/j.addr.2023.114904] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2023] [Revised: 05/18/2023] [Accepted: 05/24/2023] [Indexed: 06/03/2023]
Abstract
The global pharmaceutical market has recently shifted its focus from small molecule drugs to peptide, protein, and nucleic acid drugs, which now comprise a majority of the top-selling pharmaceutical products on the market. Although these biologics often offer improved drug specificity, new mechanisms of action, and/or enhanced efficacy, they also present new challenges, including an increased potential for degradation and a need for frequent administration via more invasive administration routes, which can limit patient access, patient adherence, and ultimately the clinical impact of these drugs. Controlled-release systems have the potential to mitigate these challenges by offering superior control over in vivo drug levels, localizing these drugs to tissues of interest (e.g., tumors), and reducing administration frequency. Unfortunately, adapting controlled-release devices to release biologics has proven difficult due to the poor stability of biologics. In this review, we summarize the current state of controlled-release peptides and proteins, discuss existing techniques used to stabilize these drugs through encapsulation, storage, and in vivo release, and provide perspective on the most promising opportunities for the clinical translation of controlled-release peptides and proteins.
Collapse
Affiliation(s)
- Miusi Shi
- Department of Bioengineering, Rice University, Houston, TX 77030, USA; The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine, Ministry of Education, School & Hospital of Stomatology, Wuhan University, Wuhan 430079, PR China
| | - Kevin J McHugh
- Department of Bioengineering, Rice University, Houston, TX 77030, USA; Department of Chemistry, Rice University, Houston, TX 77030, USA.
| |
Collapse
|
3
|
Kazmirchuk TDD, Bradbury-Jost C, Withey TA, Gessese T, Azad T, Samanfar B, Dehne F, Golshani A. Peptides of a Feather: How Computation Is Taking Peptide Therapeutics under Its Wing. Genes (Basel) 2023; 14:1194. [PMID: 37372372 PMCID: PMC10298604 DOI: 10.3390/genes14061194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Revised: 05/24/2023] [Accepted: 05/26/2023] [Indexed: 06/29/2023] Open
Abstract
Leveraging computation in the development of peptide therapeutics has garnered increasing recognition as a valuable tool to generate novel therapeutics for disease-related targets. To this end, computation has transformed the field of peptide design through identifying novel therapeutics that exhibit enhanced pharmacokinetic properties and reduced toxicity. The process of in-silico peptide design involves the application of molecular docking, molecular dynamics simulations, and machine learning algorithms. Three primary approaches for peptide therapeutic design including structural-based, protein mimicry, and short motif design have been predominantly adopted. Despite the ongoing progress made in this field, there are still significant challenges pertaining to peptide design including: enhancing the accuracy of computational methods; improving the success rate of preclinical and clinical trials; and developing better strategies to predict pharmacokinetics and toxicity. In this review, we discuss past and present research pertaining to the design and development of in-silico peptide therapeutics in addition to highlighting the potential of computation and artificial intelligence in the future of disease therapeutics.
Collapse
Affiliation(s)
- Thomas David Daniel Kazmirchuk
- Department of Biology, and the Ottawa Institute of Systems Biology (OISB), Carleton University, Ottawa, ON K1S 5B6, Canada
| | - Calvin Bradbury-Jost
- Department of Biology, and the Ottawa Institute of Systems Biology (OISB), Carleton University, Ottawa, ON K1S 5B6, Canada
| | - Taylor Ann Withey
- Department of Biology, and the Ottawa Institute of Systems Biology (OISB), Carleton University, Ottawa, ON K1S 5B6, Canada
| | - Tadesse Gessese
- Department of Biology, and the Ottawa Institute of Systems Biology (OISB), Carleton University, Ottawa, ON K1S 5B6, Canada
| | - Taha Azad
- Department of Microbiology and Infectious Diseases, Université de Sherbrooke, Sherbrooke, QC J1E 4K8, Canada
- Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke, QC J1H 5N4, Canada
| | - Bahram Samanfar
- Department of Biology, and the Ottawa Institute of Systems Biology (OISB), Carleton University, Ottawa, ON K1S 5B6, Canada
- Agriculture and Agri-Food Canada, Ottawa Research and Development Centre (ORDC), Ottawa, ON K1A 0C6, Canada
| | - Frank Dehne
- School of Computer Science, Carleton University, Ottawa, ON K1S 5B6, Canada
| | - Ashkan Golshani
- Department of Biology, and the Ottawa Institute of Systems Biology (OISB), Carleton University, Ottawa, ON K1S 5B6, Canada
| |
Collapse
|
4
|
Baryakova TH, Pogostin BH, Langer R, McHugh KJ. Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. Nat Rev Drug Discov 2023; 22:387-409. [PMID: 36973491 PMCID: PMC10041531 DOI: 10.1038/s41573-023-00670-0] [Citation(s) in RCA: 63] [Impact Index Per Article: 63.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/17/2023] [Indexed: 03/29/2023]
Abstract
Poor medication adherence is a pervasive issue with considerable health and socioeconomic consequences. Although the underlying reasons are generally understood, traditional intervention strategies rooted in patient-centric education and empowerment have proved to be prohibitively complex and/or ineffective. Formulating a pharmaceutical in a drug delivery system (DDS) is a promising alternative that can directly mitigate many common impediments to adherence, including frequent dosing, adverse effects and a delayed onset of action. Existing DDSs have already positively influenced patient acceptability and improved rates of adherence across various disease and intervention types. The next generation of systems have the potential to instate an even more radical paradigm shift by, for example, permitting oral delivery of biomacromolecules, allowing for autonomous dose regulation and enabling several doses to be mimicked with a single administration. Their success, however, is contingent on their ability to address the problems that have made DDSs unsuccessful in the past.
Collapse
Affiliation(s)
| | | | - Robert Langer
- David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - Kevin J McHugh
- Department of Bioengineering, Rice University, Houston, TX, USA.
- Department of Chemistry, Rice University, Houston, TX, USA.
| |
Collapse
|
5
|
Cheung TH, Xue C, Kurtz DA, Shoichet MS. Protein Release by Controlled Desorption from Transiently Cationic Nanoparticles. ACS APPLIED MATERIALS & INTERFACES 2023; 15:50560-50573. [PMID: 36703567 DOI: 10.1021/acsami.2c19877] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/18/2023]
Abstract
Therapeutic release from hydrogels is traditionally controlled by encapsulation within nanoparticles; however, this strategy is limited for the release of proteins due to poor efficiency and denaturation. To overcome this problem, we designed an encapsulation-free release platform where negatively charged proteins are adsorbed to the exterior of transiently cationic nanoparticles, thus allowing the nanoparticles to be formulated separately from the proteins. Release is then governed by the change in nanoparticle surface charge from positive to neutral. To achieve this, we synthesized eight zwitterionic poly(lactide-block-carboxybetaine) copolymer derivatives and formulated them into nanoparticles with differing surface chemistry. The nanoparticles were colloidally stable and lost positive charge at rates dependent on the hydrolytic stability of their surface ester groups. The nanoparticles (NPs) were dispersed in a physically cross-linked hyaluronan-based hydrogel with one of three negatively charged proteins (transferrin, panitumumab, or granulocyte-macrophage colony-stimulating factor) to assess their ability to control release. For all three proteins, dispersing NPs within the gels resulted in significant attenuation of release, with the extent modulated by the hydrolytic stability of the surface groups. Release was rapid from fast-hydrolyzing ester groups, reduced with slow-hydrolyzing bulky ester groups, and very slow with nonhydrolyzing amide groups. When positively charged lysozyme was loaded into the nanocomposite gel, there was no significant attenuation of release compared to gel alone. These data demonstrate that electrostatic interactions between the protein and NP are the primary driver of protein release from the hydrogel. All released proteins retained bioactivity as determined with in vitro cell assays. This release strategy shows tremendous versatility and provides a promising new platform for controlled release of anionic protein therapeutics.
Collapse
Affiliation(s)
- Timothy H Cheung
- Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, OntarioM5S 3H6, Canada
- Terrence Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, 160 College Street, Toronto, OntarioM5S 3E1, Canada
| | - Chang Xue
- Terrence Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, 160 College Street, Toronto, OntarioM5S 3E1, Canada
- Institute of Biomedical Engineering, University of Toronto, 164 College Street, Toronto, OntarioM5S 3G9, Canada
| | - Daniel A Kurtz
- Terrence Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, 160 College Street, Toronto, OntarioM5S 3E1, Canada
| | - Molly S Shoichet
- Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, OntarioM5S 3H6, Canada
- Terrence Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, 160 College Street, Toronto, OntarioM5S 3E1, Canada
- Institute of Biomedical Engineering, University of Toronto, 164 College Street, Toronto, OntarioM5S 3G9, Canada
- Department of Chemical Engineering and Applied Chemistry, University of Toronto, 200 College Street, Toronto, OntarioM5S 3E5, Canada
| |
Collapse
|
6
|
Abourehab MAS, Baisakhiya S, Aggarwal A, Singh A, Abdelgawad MA, Deepak A, Ansari MJ, Pramanik S. Chondroitin sulfate-based composites: a tour d'horizon of their biomedical applications. J Mater Chem B 2022; 10:9125-9178. [PMID: 36342328 DOI: 10.1039/d2tb01514e] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Chondroitin sulfate (CS), a natural anionic mucopolysaccharide, belonging to the glycosaminoglycan family, acts as the primary element of the extracellular matrix (ECM) of diverse organisms. It comprises repeating units of disaccharides possessing β-1,3-linked N-acetyl galactosamine (GalNAc), and β-1,4-linked D-glucuronic acid (GlcA), and exhibits antitumor, anti-inflammatory, anti-coagulant, anti-oxidant, and anti-thrombogenic activities. It is a naturally acquired bio-macromolecule with beneficial properties, such as biocompatibility, biodegradability, and immensely low toxicity, making it the center of attention in developing biomaterials for various biomedical applications. The authors have discussed the structure, unique properties, and extraction source of CS in the initial section of this review. Further, the current investigations on applications of CS-based composites in various biomedical fields, focusing on delivering active pharmaceutical compounds, tissue engineering, and wound healing, are discussed critically. In addition, the manuscript throws light on preclinical and clinical studies associated with CS composites. A short section on Chondroitinase ABC has also been canvassed. Finally, this review emphasizes the current challenges and prospects of CS in various biomedical fields.
Collapse
Affiliation(s)
- Mohammed A S Abourehab
- Department of Pharmaceutics, College of Pharmacy, Umm Al Qura University, Makkah 21955, Saudi Arabia. .,Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Minia University, Minia 11566, Egypt
| | - Shreya Baisakhiya
- Department of Biotechnology and Medical Engineering, National Institute of Technology Rourkela, Sector 1, Rourkela, Odisha 769008, India.,School of Chemical and Biotechnology, SASTRA Deemed University, Thanjavur, Tamil Nadu 613401, India
| | - Akanksha Aggarwal
- Delhi Institute of Pharmaceutical Sciences and Research, Delhi Pharmaceutical Sciences and Research University, New Delhi, 110017, India
| | - Anshul Singh
- Department of Chemistry, Baba Mastnath University, Rohtak-124021, India
| | - Mohamed A Abdelgawad
- Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Sakaka, Al Jouf 72341, Saudi Arabia
| | - A Deepak
- Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Chennai 600128, Tamil Nadu, India.
| | - Mohammad Javed Ansari
- Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, 11942, Saudi Arabia
| | - Sheersha Pramanik
- Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai 600036, Tamil Nadu, India.
| |
Collapse
|
7
|
Pires IS, Hammond PT, Irvine DJ. Engineering Strategies for Immunomodulatory Cytokine Therapies - Challenges and Clinical Progress. ADVANCED THERAPEUTICS 2021; 4:2100035. [PMID: 34734110 PMCID: PMC8562465 DOI: 10.1002/adtp.202100035] [Citation(s) in RCA: 39] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2021] [Indexed: 12/15/2022]
Abstract
Cytokines are immunoregulatory proteins involved in many pathological states with promising potential as therapeutic agents. A diverse array of cytokines have been studied in preclinical disease models since the 1950s, some of which became successful biopharmaceutical products with the advancement of recombinant protein technology in the 1980s. However, following these early approvals, clinical translation of these natural immune signaling molecules has been limited due to their pleiotropic action in many cell types, and the fact that they have evolved to act primarily locally in tissues. These characteristics, combined with poor pharmacokinetics, have hindered the delivery of cytokines via systemic administration routes due to dose-limiting toxicities. However, given their clinical potential and recent clinical successes in cancer immunotherapy, cytokines continue to be extensively pursued in preclinical and clinical studies, and a range of molecular and formulation engineering strategies are being applied to reduce treatment toxicity while maintaining or enhancing therapeutic efficacy. This review provides a brief background on the characteristics of cytokines and their history as clinical therapeutics, followed by a deeper discussion on the engineering strategies developed for cytokine therapies with a focus on the translational relevance of these approaches.
Collapse
Affiliation(s)
- Ivan S Pires
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, Massachusetts 02142, United States
| | - Paula T Hammond
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, Massachusetts 02142, United States
| | - Darrell J Irvine
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, Massachusetts 02142, United States
| |
Collapse
|
8
|
Wang J, Wu J, Li Y, Wen J, Cai J, Tang T, Hu X, Xiang D. The Brief Analysis of Peptide-combined Nanoparticle: Nanomedicine's Unique Value. Curr Protein Pept Sci 2021; 21:334-343. [PMID: 32039679 DOI: 10.2174/1389203721666200210103841] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2019] [Revised: 08/20/2019] [Accepted: 09/25/2019] [Indexed: 12/21/2022]
Abstract
Therapeutic peptides (TPs) are biological macromolecules which can act as neurotransmitters, hormones, ion channel ligands and growth factors. Undoubtedly, TPs are crucial in modern medicine. But low bio-stability and some special adverse reactions reduce their places to the application. With the development of nanotechnology, nanoparticles (NPs) in pharmaceutical science gained much attention. They can encapsulate the TPs into their membrane or shell. Therefore, they can protect the TPs against degradation and then increase the bioavailability, which was thought to be the biggest advantage of them. Additionally, targeting was also studied to improve the effect of TPs. However, there were some drawbacks of nano TPs like low loading efficiency and difficulty to manufacture. Nowadays, lots of studies focused on improving effect of TPs by preparing nanoparticles. In this review, we presented a brief analysis of peptide-combined nanoparticles. Their advantages and disadvantages were listed in terms of mechanism. And several examples of applications were summarized.
Collapse
Affiliation(s)
- Jiemin Wang
- Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, China.,Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha, China.,Institute of Clinical Pharmacy, Central South University, Changsha, China
| | - Junyong Wu
- Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, China.,Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha, China.,Institute of Clinical Pharmacy, Central South University, Changsha, China
| | - Yongjiang Li
- Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, China.,Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha, China.,Institute of Clinical Pharmacy, Central South University, Changsha, China
| | - Jing Wen
- Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, China.,Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha, China.,Institute of Clinical Pharmacy, Central South University, Changsha, China
| | - Jiaxin Cai
- Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, China.,Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha, China.,Institute of Clinical Pharmacy, Central South University, Changsha, China
| | - Tiantian Tang
- Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, China.,Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha, China.,Institute of Clinical Pharmacy, Central South University, Changsha, China
| | - Xiongbin Hu
- Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, China.,Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha, China.,Institute of Clinical Pharmacy, Central South University, Changsha, China
| | - Daxiong Xiang
- Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, China.,Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha, China.,Institute of Clinical Pharmacy, Central South University, Changsha, China
| |
Collapse
|
9
|
Ammar HO, Ibrahim M, Mahmoud AA, Shamma RN, El Hoffy NM. Polymer-Free Injectable In Situ Forming Nanovesicles as a New Platform for Controlled Parenteral Drug Delivery Systems. J Pharm Innov 2020. [DOI: 10.1007/s12247-020-09510-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
10
|
Application of BMP-2/FGF-2 gene-activated scaffolds for dental pulp capping. Clin Oral Investig 2020; 24:4427-4437. [PMID: 32415397 DOI: 10.1007/s00784-020-03308-2] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2019] [Accepted: 04/23/2020] [Indexed: 12/14/2022]
Abstract
OBJECTIVES To evaluate the effect of non-viral gene therapy on human dental pulp stem cells (DPSCs) in an in vitro and an ex vivo model. MATERIALS AND METHODS Nanoplexes comprising polyethyleneimine (PEI) and plasmid DNA (pDNA) encoding for fibroblast growth factor-2 (pFGF-2) and bone morphogenic protein-2 (pBMP-2) were cultured with DPSCs to evaluate cytotoxicity, protein expression, and mineralization activity. Collagen scaffolds loaded with these nanoplexes or mineral trioxide aggregate (MTA) were utilized in an ex vivo tooth culture model to assess pulp response, over a period of 14 days. All nanoplex formulations were characterized for size and zeta potential by measuring dynamic light scattering and electrophoretic mobility, respectively. RESULTS DPSCs treated with the nanoplexes showed increased cell proliferation and enhanced expression of BMP-2 and FGF-2 proteins. Collagen scaffolds containing PEI-pBMP-2 and/or pFGF-2 nanoplexes significantly increased cell proliferation, BMP-2 and FGF-2 expression, and mineralization when compared to MTA. Ex vivo histology showed a well-preserved pulp and healthy tissue in both the MTA and scaffold groups. Connective tissue in contact with the scaffold was dense and homogeneous, with some cells present in contact and within the scaffold. CONCLUSION Transfection of DPSCs with pBMP-2/pFGF-2 nanoplexes resulted in increased expression of BMP-2 and FGF-2, enhanced proliferation, and mineralization properties compared to MTA. These findings were supported by the ex vivo observations. CLINICAL RELEVANCE This biological approach in pulp capping brings new insights into the effective management of engineered pulp tissues, mainly those generated by the transplantation of DPSCs in empty root canals.
Collapse
|
11
|
Hou X, Cao B, He Y, Guo T, Li Z, Liu Y, Zhang Y, Feng N. Improved self-assembled micelles based on supercritical fluid technology as a novel oral delivery system for enhancing germacrone oral bioavailability. Int J Pharm 2019; 569:118586. [DOI: 10.1016/j.ijpharm.2019.118586] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2019] [Revised: 07/27/2019] [Accepted: 07/31/2019] [Indexed: 11/15/2022]
|
12
|
Hajavi J, Ebrahimian M, Sankian M, Khakzad MR, Hashemi M. Optimization of PLGA formulation containing protein or peptide-based antigen: Recent advances. J Biomed Mater Res A 2018; 106:2540-2551. [DOI: 10.1002/jbm.a.36423] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2017] [Revised: 02/25/2018] [Accepted: 03/15/2018] [Indexed: 12/31/2022]
Affiliation(s)
- Jafar Hajavi
- Department of Basic Sciences, Faculty of Allied Medicine; Gonabad University of Medical Sciences; Gonabad Iran
- Immunology Research Center, Medical School, Mashhad University of Medical Sciences; Mashhad Iran
| | - Mahboubeh Ebrahimian
- Division of Biotechnology, Faculty of Veterinary Medicine; Ferdowsi University of Mashhad; Mashhad Iran
| | - Mojtaba Sankian
- Immunology Research Center, Medical School, Mashhad University of Medical Sciences; Mashhad Iran
- Department of Immunology, Faculty of Medicine; Mashhad University of Medical Sciences; Mashhad Iran
| | - Mohammad Reza Khakzad
- Innovated Medical Research Center & Department of Immunology; Mashhad Branch, Islamic Azad University; Mashhad Iran
| | - Maryam Hashemi
- Nanotechnology Research Center; Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences; Mashhad Iran
| |
Collapse
|
13
|
Clements AEB, Groves ER, Chamberlain CS, Vanderby R, Murphy WL. Microparticles Locally Deliver Active Interleukin-1 Receptor Antagonist In Vivo. Adv Healthc Mater 2018; 7:e1800263. [PMID: 29974661 DOI: 10.1002/adhm.201800263] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2018] [Revised: 04/23/2018] [Indexed: 11/11/2022]
Abstract
Despite significant research in therapeutic protein delivery, localized and sustained delivery of active therapeutic proteins remains a challenge. Delivery is a particular challenge for therapeutic proteins with a short half-life. Herein, localized delivery of interleukin-1 receptor antagonist (IL-1Ra) by mineral coated microparticles (MPs) is assessed in a healing rat medial collateral ligament (MCL). The local tissue concentration and systemic serum concentration of IL-1Ra, the anti-inflammatory activity of IL-1Ra delivered with MPs, and whether IL-1Ra loaded MPs (IL-1Ra MPs) are immunogenic in a healing ligament are also examined. IL-1Ra MPs significantly increase the local concentration of IL-1Ra compared to soluble IL-1Ra at 7 and 14 days after treatment but do not elevate the systemic concentration of IL-1Ra at these time points, indicating localized delivery of IL-1Ra. IL-1Ra MPs significantly reduce inflammation caused by the MPs themselves, indicating the IL-1Ra is active. Finally, IL-1Ra MPs do not induce a foreign body response and decrease the immunogenicity of human IL-1Ra in a healing rat MCL. Overall, mineral coated microparticles have the ability to locally deliver active therapeutic proteins for an extended period of time.
Collapse
Affiliation(s)
- Anna E. B. Clements
- University of Wisconsin; Madison, 1111 Highland Ave., 5405 WIMR II Madison WI 53705 USA
| | - Emily R. Groves
- University of Wisconsin; Madison, 1111 Highland Ave., 5405 WIMR II Madison WI 53705 USA
| | - Connie S. Chamberlain
- University of Wisconsin; Madison, 1111 Highland Ave., 5405 WIMR II Madison WI 53705 USA
| | - Ray Vanderby
- University of Wisconsin; Madison, 1111 Highland Ave., 5405 WIMR II Madison WI 53705 USA
| | - William L. Murphy
- University of Wisconsin; Madison, 1111 Highland Ave., 5405 WIMR II Madison WI 53705 USA
| |
Collapse
|
14
|
Zhang Z, Liu C, Yang C, Wu Y, Yu F, Chen Y, Du J. Aptamer-Patterned Hydrogel Films for Spatiotemporally Programmable Capture and Release of Multiple Proteins. ACS APPLIED MATERIALS & INTERFACES 2018; 10:8546-8554. [PMID: 29465230 DOI: 10.1021/acsami.8b00191] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
Various hydrogels have been used for protein delivery in the treatment of human diseases. Nevertheless, it is always difficult to control the capture and release of multiple proteins in different regions and periods. This research successfully proves that multiple proteins can be captured and released from the aptamer-patterned hydrogel films with an adjustable release rate at a prospective time and in specific regions utilizing the complementary DNA strand of aptamers via photoclick chemistry and DNA hybridization. The hydrogel film is successfully applied to complex matrixes such as human serum and has excellent cytocompatibility. Thus, the aptamer-patterned hydrogel film will be a good candidate for controlled delivery of multiple proteins.
Collapse
Affiliation(s)
- Zheng Zhang
- State Key Laboratory of Marine Resource Utilization in South China Sea, College of Materials and Chemical Engineering , Hainan University , Haikou 570228 , PR China
| | - Chen Liu
- State Key Laboratory of Marine Resource Utilization in South China Sea, College of Materials and Chemical Engineering , Hainan University , Haikou 570228 , PR China
| | - Chunzheng Yang
- State Key Laboratory of Marine Resource Utilization in South China Sea, College of Materials and Chemical Engineering , Hainan University , Haikou 570228 , PR China
| | - Yuyang Wu
- State Key Laboratory of Marine Resource Utilization in South China Sea, College of Materials and Chemical Engineering , Hainan University , Haikou 570228 , PR China
| | - Feng Yu
- State Key Laboratory of Marine Resource Utilization in South China Sea, College of Materials and Chemical Engineering , Hainan University , Haikou 570228 , PR China
| | - Yong Chen
- State Key Laboratory of Marine Resource Utilization in South China Sea, College of Materials and Chemical Engineering , Hainan University , Haikou 570228 , PR China
| | - Jie Du
- State Key Laboratory of Marine Resource Utilization in South China Sea, College of Materials and Chemical Engineering , Hainan University , Haikou 570228 , PR China
| |
Collapse
|
15
|
Takata K, Takai H, Yoshizaki Y, Nagata T, Kawahara K, Yoshida Y, Kuzuya A, Ohya Y. Peptide Drug Release Behavior from Biodegradable Temperature-Responsive Injectable Hydrogels Exhibiting Irreversible Gelation. Gels 2017; 3:E38. [PMID: 30920533 PMCID: PMC6318690 DOI: 10.3390/gels3040038] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2017] [Revised: 10/13/2017] [Accepted: 10/13/2017] [Indexed: 01/05/2023] Open
Abstract
We investigated the release behavior of glucagon-like peptide-1 (GLP-1) from a biodegradable injectable polymer (IP) hydrogel. This hydrogel shows temperature-responsive irreversible gelation due to the covalent bond formation through a thiol-ene reaction. In vitro sustained release of GLP-1 from an irreversible IP formulation (F(P1/D+PA40)) was observed compared with a reversible (physical gelation) IP formulation (F(P1)). Moreover, pharmaceutically active levels of GLP-1 were maintained in blood after subcutaneous injection of the irreversible IP formulation into rats. This system should be useful for the minimally invasive sustained drug release of peptide drugs and other water-soluble bioactive reagents.
Collapse
Affiliation(s)
- Kazuyuki Takata
- Department of Chemistry and Materials Engineering, Faculty of Chemistry, Materials and Bioengineering, 3-3-35 Yamate, Suita, Osaka 564-8680, Japan.
| | - Hiroki Takai
- Department of Chemistry and Materials Engineering, Faculty of Chemistry, Materials and Bioengineering, 3-3-35 Yamate, Suita, Osaka 564-8680, Japan.
| | - Yuta Yoshizaki
- Organization for Research and Development of Innovative Science and Technology (ORDIST), Kansai University, Suita, Osaka 564-8680, Japan.
| | - Takuya Nagata
- Department of Chemistry and Materials Engineering, Faculty of Chemistry, Materials and Bioengineering, 3-3-35 Yamate, Suita, Osaka 564-8680, Japan.
| | - Keisuke Kawahara
- Department of Chemistry and Materials Engineering, Faculty of Chemistry, Materials and Bioengineering, 3-3-35 Yamate, Suita, Osaka 564-8680, Japan.
| | - Yasuyuki Yoshida
- Department of Chemistry and Materials Engineering, Faculty of Chemistry, Materials and Bioengineering, 3-3-35 Yamate, Suita, Osaka 564-8680, Japan.
- Research Fellow of Japan Society for the promotion of Science, Kojimachi, Chiyoda-ku, Tokyo 102-0083, Japan.
| | - Akinori Kuzuya
- Department of Chemistry and Materials Engineering, Faculty of Chemistry, Materials and Bioengineering, 3-3-35 Yamate, Suita, Osaka 564-8680, Japan.
- Organization for Research and Development of Innovative Science and Technology (ORDIST), Kansai University, Suita, Osaka 564-8680, Japan.
| | - Yuichi Ohya
- Department of Chemistry and Materials Engineering, Faculty of Chemistry, Materials and Bioengineering, 3-3-35 Yamate, Suita, Osaka 564-8680, Japan.
- Organization for Research and Development of Innovative Science and Technology (ORDIST), Kansai University, Suita, Osaka 564-8680, Japan.
| |
Collapse
|
16
|
Guichard MJ, Leal T, Vanbever R. PEGylation, an approach for improving the pulmonary delivery of biopharmaceuticals. Curr Opin Colloid Interface Sci 2017. [DOI: 10.1016/j.cocis.2017.08.001] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
17
|
Scott JB, Ward CL, Corona BT, Deschenes MR, Harrison BS, Saul JM, Christ GJ. Achieving Acetylcholine Receptor Clustering in Tissue-Engineered Skeletal Muscle Constructs In vitro through a Materials-Directed Agrin Delivery Approach. Front Pharmacol 2017; 7:508. [PMID: 28123368 PMCID: PMC5225105 DOI: 10.3389/fphar.2016.00508] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2016] [Accepted: 12/08/2016] [Indexed: 11/23/2022] Open
Abstract
Volumetric muscle loss (VML) can result from trauma, infection, congenital anomalies, or surgery, and produce permanent functional and cosmetic deficits. There are no effective treatment options for VML injuries, and recent advances toward development of muscle constructs lack the ability to achieve innervation necessary for long-term function. We sought to develop a proof-of-concept biomaterial construct that could achieve acetylcholine receptor (AChR) clustering on muscle-derived cells (MDCs) in vitro. The approach consisted of the presentation of neural (Z+) agrin from the surface of microspheres embedded with a fibrin hydrogel to muscle cells (C2C12 cell line or primary rat MDCs). AChR clustering was spatially restricted to areas of cell (C2C12)-microsphere contact when the microspheres were delivered in suspension or when they were incorporated into a thin (2D) fibrin hydrogel. AChR clusters were observed from 16 to 72 h after treatment when Z+ agrin was adsorbed to the microspheres, and for greater than 120 h when agrin was covalently coupled to the microspheres. Little to no AChR clustering was observed when agrin-coated microspheres were delivered from specially designed 3D fibrin constructs. However, cyclic stretch in combination with agrin-presenting microspheres led to dramatic enhancement of AChR clustering in cells cultured on these 3D fibrin constructs, suggesting a synergistic effect between mechanical strain and agrin stimulation of AChR clustering in vitro. These studies highlight a strategy for maintaining a physiological phenotype characterized by motor endplates of muscle cells used in tissue engineering strategies for muscle regeneration. As such, these observations may provide an important first step toward improving function of tissue-engineered constructs for treatment of VML injuries.
Collapse
Affiliation(s)
- John B Scott
- Wake Forest Institute for Regenerative Medicine, Wake Forest University Health Sciences, Winston-SalemNC, USA; Virginia Tech - Wake Forest University School of Biomedical Engineering and Sciences, Wake Forest University Biomedical Engineering, Winston-SalemNC, USA
| | - Catherine L Ward
- Wake Forest Institute for Regenerative Medicine, Wake Forest University Health Sciences, Winston-SalemNC, USA; US Army Institute for Surgical Research, San AntonioTX, USA
| | - Benjamin T Corona
- Wake Forest Institute for Regenerative Medicine, Wake Forest University Health Sciences, Winston-SalemNC, USA; US Army Institute for Surgical Research, San AntonioTX, USA
| | - Michael R Deschenes
- Department of Neuroscience, College of William and Mary, Williamsburg VA, USA
| | - Benjamin S Harrison
- Wake Forest Institute for Regenerative Medicine, Wake Forest University Health Sciences, Winston-SalemNC, USA; Virginia Tech - Wake Forest University School of Biomedical Engineering and Sciences, Wake Forest University Biomedical Engineering, Winston-SalemNC, USA
| | - Justin M Saul
- Department of Chemical, Paper and Biomedical Engineering, Miami University, Oxford OH, USA
| | - George J Christ
- Wake Forest Institute for Regenerative Medicine, Wake Forest University Health Sciences, Winston-SalemNC, USA; Department of Biomedical Engineering and Department of Orthopaedic Surgery, University of Virginia, CharlottesvilleVA, USA
| |
Collapse
|
18
|
Bolhassani A, Jafarzade BS, Mardani G. In vitro and in vivo delivery of therapeutic proteins using cell penetrating peptides. Peptides 2017; 87:50-63. [PMID: 27887988 DOI: 10.1016/j.peptides.2016.11.011] [Citation(s) in RCA: 162] [Impact Index Per Article: 23.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/23/2016] [Revised: 11/18/2016] [Accepted: 11/21/2016] [Indexed: 02/07/2023]
Abstract
The failure of proteins to penetrate mammalian cells or target tumor cells restricts their value as therapeutic tools in a variety of diseases such as cancers. Recently, protein transduction domains (PTDs) or cell penetrating peptides (CPPs) have been shown to promote the delivery of therapeutic proteins or peptides into live cells. The successful delivery of proteins mainly depends on their physicochemical properties. Although, linear cell penetrating peptides are one of the most effective delivery vehicles; but currently, cyclic CPPs has been developed to potently transport bioactive full-length proteins into cells. Up to now, several small protein transduction domains from viral proteins including Tat or VP22 could be fused to other peptides or proteins to entry them in various cell types at a dose-dependent approach. A major disadvantage of PTD-fusion proteins is primary uptake into endosomal vesicles leading to inefficient release of the fusion proteins into the cytosol. Recently, non-covalent complex formation (Chariot) between proteins and CPPs has attracted a special interest to overcome some delivery limitations (e.g., toxicity). Many preclinical and clinical trials of CPP-based delivery are currently under evaluation. Generally, development of more efficient protein transduction domains would significantly increase the potency of protein therapeutics. Moreover, the synergistic or combined effects of CPPs with other delivery systems for protein/peptide drug delivery would promote their therapeutic effects in cancer and other diseases. In this review, we will describe the functions and implications of CPPs for delivering the therapeutic proteins or peptides in preclinical and clinical studies.
Collapse
Affiliation(s)
- Azam Bolhassani
- Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran.
| | | | - Golnaz Mardani
- Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran
| |
Collapse
|
19
|
Feng Y, Wang F, Zhang XW, Bhutani H, Ye B. Characterizations and bioactivities of abendazole sulfoxide-loaded thermo-sensitive hydrogel. Parasitol Res 2016; 116:921-928. [PMID: 28028630 DOI: 10.1007/s00436-016-5365-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2016] [Accepted: 12/20/2016] [Indexed: 01/10/2023]
Abstract
Albendazole (ABZ), a widely used anthelmintic, attributes its primary metabolite-albendazole sulfoxide (ABZSO)-as an effective agent against helminthes. For a purpose of long-lasting releasing ABZSO in a special lesion, the present study successfully manufactured ABZSO-loaded thermo-sensitive hydrogel, which was proved by FTIR and 1H NMR, in the interim; in vitro and in vivo behaviors of the thermo-sensitive hydrogel containing ABZSO were studied too. The in vivo pharmacokinetics parameters indicated ABZSO-loaded hydrogel as a better choice for sustained release compared with simple ABZSO. Additionally, the effect of the prepared hydrogels against helminth was investigated by the lethality of Caenorhabditis elegans, the results indicated that the lethality of ABZSO-loaded hydrogel (1, 2, and 4 mg/ml, respectively) on C. elegans was higher than that of PLGA-PEG-PLGA group (P < 0.05). It suggested that the hydrogels loaded with albendazole sulfoxide could be considered highly effective against the nematode C. elegans.
Collapse
Affiliation(s)
- Yi Feng
- Department of Pathogenic Biology, Chongqing Medical University, Chongqing, 400016, People's Republic of China
| | - Fen Wang
- Department of Pathogenic Biology, Chongqing Medical University, Chongqing, 400016, People's Republic of China
| | - Xue-Wei Zhang
- Department of Pathogenic Biology, Chongqing Medical University, Chongqing, 400016, People's Republic of China
| | - Harshit Bhutani
- Batch 2013, Clinical Medicine, College of Overseas Student, Chongqing Medical University, Chongqing, 400016, People's Republic of China
| | - Bin Ye
- Department of Pathogenic Biology, Chongqing Medical University, Chongqing, 400016, People's Republic of China. .,Research Center for Molecule Medicine and Tumor, Chongqing Medical University, Chongqing, 400016, People's Republic of China.
| |
Collapse
|
20
|
da Cunha CRA, da Silva LCN, Almeida FJF, Ferraz MS, Varejão N, Cartaxo MFDS, de Miranda RDCM, de Aguiar FCA, Santos NPDS, Coelho LCBB, Santos-Magalhães NS, Correia MTDS. Encapsulation into Stealth Liposomes Enhances the Antitumor Action of Recombinant Cratylia mollis Lectin Expressed in Escherichia coli. Front Microbiol 2016; 7:1355. [PMID: 27695439 PMCID: PMC5026010 DOI: 10.3389/fmicb.2016.01355] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2016] [Accepted: 08/16/2016] [Indexed: 11/13/2022] Open
Abstract
This study evaluated the in vivo antitumor potential of the recombinant lectin from seeds of Cratylia mollis (rCramoll) expressed in Escherichia coli, free or encapsulated in stealth liposomes, using mice transplanted with sarcoma 180. rCramoll-loaded stealth liposomes (rCramoll-lipo) were formulated by hydration of the lipid film followed by cycles of freezing and thawing, and about 60% of rCramoll was encapsulated. This novel preparation showed particle size, polydispersity index, and pH suitable for the evaluation of antitumor activity in vivo. Tumor growth inhibition rates were 59% for rCramoll and 75% for rCramoll-lipo. Histopathological analysis of the experimental groups showed that both free and encapsulated lectin caused no changes in the kidneys of animals. Hematological analysis revealed that treatment with rCramoll-lipo significantly increased leukocyte concentration when compared with the untreated and rCramoll group. In conclusion, the encapsulation of rCramoll in stealth liposomes improves its antitumor activity without substantial toxicity; this approach was more successful than the previous results reported for pCramoll loaded into conventional liposomes. At this point, a crucial difference between the antitumor action of free and encapsulated rCramoll was found along with their effects on immune cells. Further investigations are required to elucidate the mechanism(s) of the antitumor effect induced by rCramoll.
Collapse
Affiliation(s)
- Cássia R. A. da Cunha
- Laboratório de Bioquímica de Proteínas, Departamento de Bioquímica, Universidade Federal de PernambucoRecife, Brazil
| | - Luís C. N. da Silva
- Laboratório de Bioquímica de Proteínas, Departamento de Bioquímica, Universidade Federal de PernambucoRecife, Brazil
- Programa de Pós-Graduação em Biologia Parasitária, Universidade CeumaSão Luís, Brazil
| | - Fábio J. F. Almeida
- Laboratório de Imunopatologia Keizo-Asami, Universidade Federal de PernambucoRecife, Brazil
| | - Milena S. Ferraz
- Laboratório de Imunopatologia Keizo-Asami, Universidade Federal de PernambucoRecife, Brazil
| | - Nathalia Varejão
- Laboratório de Agregação de Proteínas e Amiloidoses, Instituto de Bioquímica Médica, Universidade Federal do Rio de JaneiroRio de Janeiro, Brazil
| | | | | | | | | | - Luana C. B. B. Coelho
- Laboratório de Bioquímica de Proteínas, Departamento de Bioquímica, Universidade Federal de PernambucoRecife, Brazil
| | | | - Maria T. dos Santos Correia
- Laboratório de Bioquímica de Proteínas, Departamento de Bioquímica, Universidade Federal de PernambucoRecife, Brazil
| |
Collapse
|
21
|
Ahmed OAA, Zidan AS, Khayat M. Mechanistic analysis of Zein nanoparticles/PLGA triblock in situ forming implants for glimepiride. Int J Nanomedicine 2016; 11:543-55. [PMID: 26893561 PMCID: PMC4745829 DOI: 10.2147/ijn.s99731] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Objectives The study aims at applying pharmaceutical nanotechnology and D-optimal fractional factorial design to screen and optimize the high-risk variables affecting the performance of a complex drug delivery system consisting of glimepiride–Zein nanoparticles and inclusion of the optimized formula with thermoresponsive triblock copolymers in in situ gel. Methods Sixteen nanoparticle formulations were prepared by liquid–liquid phase separation method according to the D-optimal fractional factorial design encompassing five variables at two levels. The responses investigated were glimepiride entrapment capacity (EC), particle size and size distribution, zeta potential, and in vitro drug release from the prepared nanoparticles. Furthermore, the feasibility of embedding the optimized Zein-based glimepiride nanoparticles within thermoresponsive triblock copolymers poly(lactide-co-glycolide)-block-poly(ethylene glycol)-block-poly(lactide-co-glycolide) in in situ gel was evaluated for controlling glimepiride release rate. Results Through the systematic optimization phase, improvement of glimepiride EC of 33.6%, nanoparticle size of 120.9 nm with a skewness value of 0.2, zeta potential of 11.1 mV, and sustained release features of 3.3% and 17.3% drug released after 2 and 24 hours, respectively, were obtained. These desirability functions were obtained at Zein and glimepiride loadings of 50 and 75 mg, respectively, utilizing didodecyldimethylammonium bromide as a stabilizer at 0.1% and 90% ethanol as a common solvent. Moreover, incorporating this optimized formulation in triblock copolymers-based in situ gel demonstrated pseudoplastic behavior with reduction of drug release rate as the concentration of polymer increased. Conclusion This approach to control the release of glimepiride using Zein nanoparticles/triblock copolymers-based in situ gel forming intramuscular implants could be useful for improving diabetes treatment effectiveness.
Collapse
Affiliation(s)
- Osama Abdelhakim Aly Ahmed
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Minia University, Minia, Egypt
| | - Ahmed Samir Zidan
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt
| | - Maan Khayat
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
| |
Collapse
|
22
|
Loscri V, Matekovits L, Peter I, Vegni AM. In-Body Network Biomedical Applications: From Modeling to Experimentation. IEEE Trans Nanobioscience 2016; 15:53-61. [DOI: 10.1109/tnb.2016.2521386] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
23
|
Barthold S, Kletting S, Taffner J, de Souza Carvalho-Wodarz C, Lepeltier E, Loretz B, Lehr CM. Preparation of nanosized coacervates of positive and negative starch derivatives intended for pulmonary delivery of proteins. J Mater Chem B 2016; 4:2377-2386. [DOI: 10.1039/c6tb00178e] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Use of charged starch-derivatives as nanoscaled protein carriers and their in vitro evaluation.
Collapse
Affiliation(s)
- S. Barthold
- Department Drug Delivery
- Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS)
- Helmholtz-Centre for Infection Research (HZI)
- Saarbrücken
- Germany
| | - S. Kletting
- Department Drug Delivery
- Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS)
- Helmholtz-Centre for Infection Research (HZI)
- Saarbrücken
- Germany
| | - J. Taffner
- Department Drug Delivery
- Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS)
- Helmholtz-Centre for Infection Research (HZI)
- Saarbrücken
- Germany
| | - C. de Souza Carvalho-Wodarz
- Department Drug Delivery
- Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS)
- Helmholtz-Centre for Infection Research (HZI)
- Saarbrücken
- Germany
| | - E. Lepeltier
- Department Drug Delivery
- Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS)
- Helmholtz-Centre for Infection Research (HZI)
- Saarbrücken
- Germany
| | - B. Loretz
- Department Drug Delivery
- Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS)
- Helmholtz-Centre for Infection Research (HZI)
- Saarbrücken
- Germany
| | - C.-M. Lehr
- Department Drug Delivery
- Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS)
- Helmholtz-Centre for Infection Research (HZI)
- Saarbrücken
- Germany
| |
Collapse
|
24
|
Soudry-Kochavi L, Naraykin N, Nassar T, Benita S. Improved oral absorption of exenatide using an original nanoencapsulation and microencapsulation approach. J Control Release 2015; 217:202-10. [PMID: 26381898 DOI: 10.1016/j.jconrel.2015.09.012] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2015] [Revised: 09/06/2015] [Accepted: 09/09/2015] [Indexed: 11/25/2022]
Abstract
Oral delivery is the most convenient and favorable route for chronic administration of peptides and proteins to patients. However, many obstacles are faced when developing such a delivery route. Nanoparticles (NPs) are among the leading innovative solutions for delivery of these drugs. Exenatide is a peptidic drug administered subcutaneously (SC) twice a day chronically as an add-on therapy for the worldwide pandemic disease, diabetes. Many attempts to develop oral nanocarriers for this drug have been unsuccessful due to the inability to retain this hydrophilic macromolecule under sink conditions or to find a suitable cross-linker which does not harm the chemical integrity of the peptide. In this study, we report about an original oral delivery solution based on a mixture of albumin and dextran NPs cross-linked using sodium trimetaphosphate (STMP). Moreover, we suggest a second defense line of gastro-resistant microparticles (MPs) composed of an appropriate ratio of Eudragit® L100-55 (Eudragit L) and hydroxypropylmethylcellulose (HPMC), for additional protection to these NPs presumably allowing them to be absorbed in the intestine intact. Our results demonstrate that such a system indeed improves the relative oral bioavailability of exenatide to a level of about 77% compared to subcutaneous injection due to the presence of dextran in the coating wall of the NPs which apparently promotes the lymphatic uptake in the enterocytes. This technology may be a milestone on the way to deliver other peptides and proteins orally.
Collapse
Affiliation(s)
- Liat Soudry-Kochavi
- The Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Ein Kerem, 9112102, Israel
| | - Natalya Naraykin
- The Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Ein Kerem, 9112102, Israel
| | - Taher Nassar
- The Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Ein Kerem, 9112102, Israel
| | - Simon Benita
- The Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Ein Kerem, 9112102, Israel.
| |
Collapse
|
25
|
Leonaviciute G, Bernkop-Schnürch A. Self-emulsifying drug delivery systems in oral (poly)peptide drug delivery. Expert Opin Drug Deliv 2015; 12:1703-16. [PMID: 26477549 DOI: 10.1517/17425247.2015.1068287] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
INTRODUCTION Oral administration of most therapeutic peptides and proteins is mainly restricted due to the enzymatic and absorption membrane barrier of the GI tract. In order to overcome these barriers, various technologies have been explored. Among them, self-emulsifying drug delivery systems (SEDDS) received considerable attention as potential carriers to facilitate oral peptide and protein delivery in recent years. AREAS COVERED This review article intends to summarize physiological barriers which limit the bioavailability of orally administrated peptide and protein drugs. Furthermore, the potential of SEDDS to protect incorporated peptides and proteins towards peptidases and proteases and to penetrate the mucus layer is reviewed. Their permeation-enhancing properties and their ability to release the drug in a controlled way are described. Moreover, this review covers the results of in vivo studies providing evidence for this promising approach. EXPERT OPINION As SEDDS can: i) provide a protective effect towards a presystemic metabolism; ii) efficiently permeate the intestinal mucus gel layer in order to reach the absorption membrane; and iii) be produced in a very simple and cost-effective manner, they are a promising tool for oral peptide and protein drug delivery.
Collapse
Affiliation(s)
- Gintare Leonaviciute
- a Leopold - Franzens University Innsbruck, Institut of Pharmacy, Center for Chemistry and Biomedicine, Department of Pharmaceutical Technology , Innrain 80/82, Innsbruck, Austria +43 512 507 58601 ; +43 512 507 58699 ;
| | - Andreas Bernkop-Schnürch
- a Leopold - Franzens University Innsbruck, Institut of Pharmacy, Center for Chemistry and Biomedicine, Department of Pharmaceutical Technology , Innrain 80/82, Innsbruck, Austria +43 512 507 58601 ; +43 512 507 58699 ;
| |
Collapse
|
26
|
Zhu C, Huang Y, Zhang X, Mei L, Pan X, Li G, Wu C. Comparative studies on exenatide-loaded poly ( d , l -lactic-co-glycolic acid) microparticles prepared by a novel ultra-fine particle processing system and spray drying. Colloids Surf B Biointerfaces 2015; 132:103-10. [DOI: 10.1016/j.colsurfb.2015.05.001] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2014] [Revised: 04/01/2015] [Accepted: 05/03/2015] [Indexed: 11/26/2022]
|
27
|
Characterization of Multi-Sourced Diclofenac Sodium Extended-Release Tablet Dissolution Profiles: A New Approach to Establish an In vitro-In vivo Correlation Based on Multiple Integral Response Surface. J Pharm Innov 2015. [DOI: 10.1007/s12247-015-9227-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
28
|
Venuti V, Rossi B, D'Amico F, Mele A, Castiglione F, Punta C, Melone L, Crupi V, Majolino D, Trotta F, Gessini A, Masciovecchio C. Combining Raman and infrared spectroscopy as a powerful tool for the structural elucidation of cyclodextrin-based polymeric hydrogels. Phys Chem Chem Phys 2015; 17:10274-82. [DOI: 10.1039/c5cp00607d] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
UV Raman spectroscopy and infrared spectroscopy have been efficiently implemented for the structural and dynamic elucidation of cyclodextrin-based polymeric hydrogels.
Collapse
|
29
|
Ibraheem D, Elaissari A, Fessi H. Administration strategies for proteins and peptides. Int J Pharm 2014; 477:578-89. [PMID: 25445533 DOI: 10.1016/j.ijpharm.2014.10.059] [Citation(s) in RCA: 64] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2014] [Revised: 10/24/2014] [Accepted: 10/28/2014] [Indexed: 02/01/2023]
Abstract
Proteins are a vital constituent of the body as they perform many of its major physiological and biological processes. Recently, proteins and peptides have attracted much attention as potential treatments for various dangerous and traditionally incurable diseases such as cancer, AIDS, dwarfism and autoimmune disorders. Furthermore, proteins could be used for diagnostics. At present, most therapeutic proteins are administered via parenteral routes that have many drawbacks, for example, they are painful, expensive and may cause toxicity. Finding more effective, easier and safer alternative routes for administering proteins and peptides is the key to therapeutic and commercial success. In this context, much research has been focused on non-invasive routes such as nasal, pulmonary, oral, ocular, and rectal for administering proteins and peptides. Unfortunately, the widespread use of proteins and peptides as drugs is still faced by many obstacles such as low bioavailability, short half-life in the blood stream, in vivo instability and numerous other problems. In order to overcome these hurdled and improve protein/peptide drug efficacy, various strategies have been developed such as permeability enhancement, enzyme inhibition, protein structure modification and protection by encapsulation. This review provides a detailed description of all the previous points in order to highlight the importance and potential of proteins and peptides as drugs.
Collapse
Affiliation(s)
- D Ibraheem
- University of Lyon, F-69622, Lyon, France, University Lyon-1, Villeurbanne, CNRS, UMR-5007, LAGEP- CPE, 43 bd 11 Novembre 1918, F-69622 Villeurbanne, France
| | - A Elaissari
- University of Lyon, F-69622, Lyon, France, University Lyon-1, Villeurbanne, CNRS, UMR-5007, LAGEP- CPE, 43 bd 11 Novembre 1918, F-69622 Villeurbanne, France
| | - H Fessi
- University of Lyon, F-69622, Lyon, France, University Lyon-1, Villeurbanne, CNRS, UMR-5007, LAGEP- CPE, 43 bd 11 Novembre 1918, F-69622 Villeurbanne, France.
| |
Collapse
|
30
|
An overview of clinical and commercial impact of drug delivery systems. J Control Release 2014; 190:15-28. [PMID: 24747160 DOI: 10.1016/j.jconrel.2014.03.053] [Citation(s) in RCA: 305] [Impact Index Per Article: 30.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2014] [Revised: 03/21/2014] [Accepted: 03/28/2014] [Indexed: 10/25/2022]
Abstract
Drug delivery systems are widely researched and developed to improve the delivery of pharmaceutical compounds and molecules. The last few decades have seen a marked growth of the field fueled by increased number of researchers, research funding, venture capital and the number of start-ups. Collectively, the growth has led to novel systems that make use of micro/nano-particles, transdermal patches, inhalers, drug reservoir implants and antibody-drug conjugates. While the increased research activity is clearly an indication of proliferation of the field, clinical and commercial translation of early-stage research ideas is critically important for future growth and interest in the field. Here, we will highlight some of the examples of novel drug delivery systems that have undergone such translation. Specifically, we will discuss the developments, advantages, limitations and lessons learned from: (i) microparticle-based depot formulations, (ii) nanoparticle-based cancer drugs, (iii) transdermal systems, (iv) oral drug delivery systems, (v) pulmonary drug delivery, (vi) implants and (vii) antibody-drug conjugates. These systems have impacted treatment of many prevalent diseases including diabetes, cancer and cardiovascular diseases, among others. At the same time, these systems are integral and enabling components of products that collectively generate annual revenues exceeding US $100 billion. These examples provide strong evidence of the clinical and commercial impact of drug delivery systems.
Collapse
|
31
|
Schädlich A, Kempe S, Mäder K. Non-invasive in vivo characterization of microclimate pH inside in situ forming PLGA implants using multispectral fluorescence imaging. J Control Release 2014; 179:52-62. [PMID: 24503251 DOI: 10.1016/j.jconrel.2014.01.024] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2013] [Revised: 01/22/2014] [Accepted: 01/26/2014] [Indexed: 11/16/2022]
Abstract
The pH inside drug delivery systems influences directly the physical and chemical behavior of its ingredients specifically their solubility and stability. These properties significantly affect the release performance of the formulations as well as the pharmacological effect. Therefore, the determination of the microclimate pH (μpH) inside the drug delivery systems is of great importance and interest. Implants are considered to be attractive parenteral drug delivery systems used for the long-term application of drugs and of peptides. Poly(lactide-co-glycolide) (PLGA) is the most frequently used and extensively researched polymer for implant preparation. However it is known that the microclimate pH (μpH) within the PLGA implants can also drop dramatically. This pH drop can cause peptide or protein instabilities as well as drug insolubilities and further decomposition. Although the internal pH behavior of PLGA implants and microparticles has been studied in vitro, no data about the μpH behavior in in situ forming implants has yet been described. This is due to the fact, that there is no reliable non-invasive method available to measure directly and continuously the pH in vivo. Therefore, the question if in vitro measurement results are potentially assignable remains unclear. In this study, the μpH of in situ forming PLGA implants were mapped in vitro, in vivo, and ex vivo. A non-invasive in vivo pH measurement method using the multispectral Maestro fluorescence imaging system was developed. The in vivo experiments performed, not only enabled the authors of this article to make certain assumptions about μpH behavior but also emphasized certain expectations regarding the solvent replacement in the core area of the implant as well as the release profile of hydrophilic substances. The experiments emphasized the broad application range of the fluorescence imaging technique for non-invasive monitoring of μpH values in drug delivery systems in vivo.
Collapse
Affiliation(s)
- Andreas Schädlich
- Faculty of Biosciences, Institute of Pharmacy, Martin Luther University Halle-Wittenberg, Wolfgang-Langenbeck-Str. 4, 06120 Halle (Saale), Germany
| | - Sabine Kempe
- Faculty of Biosciences, Institute of Pharmacy, Martin Luther University Halle-Wittenberg, Wolfgang-Langenbeck-Str. 4, 06120 Halle (Saale), Germany
| | - Karsten Mäder
- Faculty of Biosciences, Institute of Pharmacy, Martin Luther University Halle-Wittenberg, Wolfgang-Langenbeck-Str. 4, 06120 Halle (Saale), Germany.
| |
Collapse
|
32
|
Papa S, Ferrari R, De Paola M, Rossi F, Mariani A, Caron I, Sammali E, Peviani M, Dell'Oro V, Colombo C, Morbidelli M, Forloni G, Perale G, Moscatelli D, Veglianese P. Polymeric nanoparticle system to target activated microglia/macrophages in spinal cord injury. J Control Release 2013; 174:15-26. [PMID: 24225226 DOI: 10.1016/j.jconrel.2013.11.001] [Citation(s) in RCA: 80] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2013] [Revised: 10/11/2013] [Accepted: 11/01/2013] [Indexed: 01/24/2023]
Abstract
The possibility to control the fate of the cells responsible for secondary mechanisms following spinal cord injury (SCI) is one of the most relevant challenges to reduce the post traumatic degeneration of the spinal cord. In particular, microglia/macrophages associated inflammation appears to be a self-propelling mechanism which leads to progressive neurodegeneration and development of persisting pain state. In this study we analyzed the interactions between poly(methyl methacrylate) nanoparticles (PMMA-NPs) and microglia/macrophages in vitro and in vivo, characterizing the features that influence their internalization and ability to deliver drugs. The uptake mechanisms of PMMA-NPs were in-depth investigated, together with their possible toxic effects on microglia/macrophages. In addition, the possibility to deliver a mimetic drug within microglia/macrophages was characterized in vitro and in vivo. Drug-loaded polymeric NPs resulted to be a promising tool for the selective administration of pharmacological compounds in activated microglia/macrophages and thus potentially able to counteract relevant secondary inflammatory events in SCI.
Collapse
Affiliation(s)
- Simonetta Papa
- IRCCS Istituto di Ricerche Farmacologiche "Mario Negri", Dipartimento di Neuroscienze, via La Masa 19, 20156 Milan, Italy
| | - Raffaele Ferrari
- Politecnico di Milano, Dipartimento di Chimica, Materiali e Ingegneria Chimica "Giulio Natta", via Mancinelli 7, 20131 Milan, Italy
| | - Massimiliano De Paola
- IRCCS Istituto di Ricerche Farmacologiche "Mario Negri", Dipartimento di Ambiente e Salute, via La Masa 19, 20156 Milan, Italy
| | - Filippo Rossi
- Politecnico di Milano, Dipartimento di Chimica, Materiali e Ingegneria Chimica "Giulio Natta", via Mancinelli 7, 20131 Milan, Italy
| | - Alessandro Mariani
- IRCCS Istituto di Ricerche Farmacologiche "Mario Negri", Dipartimento di Ambiente e Salute, via La Masa 19, 20156 Milan, Italy
| | - Ilaria Caron
- IRCCS Istituto di Ricerche Farmacologiche "Mario Negri", Dipartimento di Neuroscienze, via La Masa 19, 20156 Milan, Italy
| | - Eliana Sammali
- IRCCS Istituto di Ricerche Farmacologiche "Mario Negri", Dipartimento di Neuroscienze, via La Masa 19, 20156 Milan, Italy
| | - Marco Peviani
- Università di Pavia, Dipartimento di Biologia e Biotecnologie "L. Spallanzani", via Ferrata, 9, 27100 Pavia, Italy
| | - Valentina Dell'Oro
- IRCCS Istituto di Ricerche Farmacologiche "Mario Negri", Dipartimento di Neuroscienze, via La Masa 19, 20156 Milan, Italy
| | - Claudio Colombo
- Politecnico di Milano, Dipartimento di Chimica, Materiali e Ingegneria Chimica "Giulio Natta", via Mancinelli 7, 20131 Milan, Italy
| | - Massimo Morbidelli
- Institute for Chemical and Bioengineering, ETH Zurich, Campus Hoenggerberg, HCI F125, Wolfgang Pauli Str. 10, 8093 Zurich, Switzerland
| | - Gianluigi Forloni
- IRCCS Istituto di Ricerche Farmacologiche "Mario Negri", Dipartimento di Neuroscienze, via La Masa 19, 20156 Milan, Italy
| | - Giuseppe Perale
- Politecnico di Milano, Dipartimento di Chimica, Materiali e Ingegneria Chimica "Giulio Natta", via Mancinelli 7, 20131 Milan, Italy; Department of Innovative Technologies, University of Applied Sciences and Arts of Southern Switzerland, SUPSI, via Cantonale, CH-6928 Manno, Switzerland; Swiss Institute for Regenerative Medicine, CH-6807 Taverne, Switzerland
| | - Davide Moscatelli
- Politecnico di Milano, Dipartimento di Chimica, Materiali e Ingegneria Chimica "Giulio Natta", via Mancinelli 7, 20131 Milan, Italy
| | - Pietro Veglianese
- IRCCS Istituto di Ricerche Farmacologiche "Mario Negri", Dipartimento di Neuroscienze, via La Masa 19, 20156 Milan, Italy.
| |
Collapse
|
33
|
Gamboa JM, Leong KW. In vitro and in vivo models for the study of oral delivery of nanoparticles. Adv Drug Deliv Rev 2013; 65:800-10. [PMID: 23415952 DOI: 10.1016/j.addr.2013.01.003] [Citation(s) in RCA: 188] [Impact Index Per Article: 17.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2012] [Revised: 11/28/2012] [Accepted: 01/30/2013] [Indexed: 12/31/2022]
Abstract
Oral delivery is an attractive route to deliver therapeutics via nanoparticles due to its ease of administration and patient compliance. This review discusses laboratory techniques for studying oral delivery of nanoparticles, which offer protection of cargo through the gastrointestinal tract. Some of the difficulties in modeling oral delivery include the harsh acidic environment, variable pH, and the tight monolayer of endothelial cells present throughout the gastrointestinal tract. The use of in vitro techniques including the Transwell ® system, simulated gastric/intestinal fluid, and diffusion chambers addresses these challenges. When studying effects after oral delivery in vivo, bioimaging of nanoparticle biodistribution using radioactive markers has been popular. Functional assays such as immune response and systemic protein concentration analysis can further define the merits of the oral delivery systems. As biologics become increasingly more important in chronic therapies, nanoparticle-mediated oral delivery will assume greater prominence, and more sophisticated in vitro and in vivo models will be required.
Collapse
|
34
|
Agarwal P, Rupenthal ID. Injectable implants for the sustained release of protein and peptide drugs. Drug Discov Today 2013; 18:337-49. [PMID: 23410799 DOI: 10.1016/j.drudis.2013.01.013] [Citation(s) in RCA: 111] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2012] [Revised: 11/02/2012] [Accepted: 01/14/2013] [Indexed: 12/20/2022]
Abstract
Protein and peptide macromolecules have emerged as promising therapeutic agents in recent years. However, their delivery to the target site can be challenging owing to their susceptibility to denaturation and degradation, short half-life and, therefore, poor bioavailability. In situ-forming implants present an attractive parenteral delivery platform for proteins and peptides because of their ease of application, sustained-release properties, tissue biocompatibility and simple manufacture. In this review, we discuss the various mechanisms by which polymer systems assemble in situ to form implant devices for sustained release of therapeutic macromolecules, and highlight recent advances in polymer systems that gel in response to a combination of these mechanisms. Finally, we examine release mechanisms, marketed products and limitations of injectable implants.
Collapse
Affiliation(s)
- Priyanka Agarwal
- Drug Delivery Research Unit, School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| | | |
Collapse
|
35
|
Tang Y, Ren Y, Shi X. Bifunctional Mesoporous Zirconium Phosphonates for Delivery of Nucleic Acids. Inorg Chem 2013; 52:1388-97. [DOI: 10.1021/ic3020942] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Yan Tang
- Institute of Chemistry
for Functionalized Materials, School of Chemistry and Chemical Engineering, Liaoning Normal University, 850 Huanghe Road, Dalian
116029, China
| | - Yubao Ren
- Institute of Chemistry
for Functionalized Materials, School of Chemistry and Chemical Engineering, Liaoning Normal University, 850 Huanghe Road, Dalian
116029, China
| | - Xin Shi
- Institute of Chemistry
for Functionalized Materials, School of Chemistry and Chemical Engineering, Liaoning Normal University, 850 Huanghe Road, Dalian
116029, China
| |
Collapse
|
36
|
Jorgensen L, Groenning M, Roest N, Pinholt C, van de Weert M. The challenges in and importance of analysing protein structure and physical stability in complex formulations. J Drug Deliv Sci Technol 2013. [DOI: 10.1016/s1773-2247(13)50051-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
37
|
Zadymova NM, Poteshnova MV, Kulichikhin VG. Properties of oil1/water/oil2 double emulsions containing lipophilic acrylic polymer. COLLOID JOURNAL 2012. [DOI: 10.1134/s1061933x12050146] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
38
|
Jin H, Li S, Hu D, Zhao Y. Preparation of PLA-PEG nanoparticles by the solution enhanced dispersion with enhanced mass transfer using ultrasound in supercritical CO2. POWDER TECHNOL 2012. [DOI: 10.1016/j.powtec.2012.04.050] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
39
|
Ubale RV, D'Souza MJ, Infield DT, McCarty NA, Zughaier SM. Formulation of meningococcal capsular polysaccharide vaccine-loaded microparticles with robust innate immune recognition. J Microencapsul 2012; 30:28-41. [PMID: 22657751 DOI: 10.3109/02652048.2012.692402] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Neisseria meningitidis is a leading cause of bacterial meningitis and sepsis associated with a high mortality rate. Capsular polysaccharides (CPSs) are a major virulence factor and form the basis for serogroup designation and protective vaccines. The current polysaccharide meningococcal vaccines are available but are very expensive and require chemical conjugation. Here, we report a novel meningococcal vaccine formulation consisting of meningococcal CPS polymers encapsulated in albumin-based biodegradable microparticles that slowly release antigen and induce robust innate immune responses. Vaccines that elicit innate immunity are reported to have enhanced and protective adaptive immune responses. In this study, the meningococcal CPS-loaded microparticles, but not the empty microparticles, induced the release of IL-8, TNF-α and IL-1β, enhanced phagocytic capacity and induced robust autophagy in macrophages. The novel meningococcal vaccine microparticles are robustly taken up by macrophages and elicit strong innate immune responses that enhance antigen presentation which is a prerequisite for inducing adaptive immunity.
Collapse
Affiliation(s)
- Ruhi V Ubale
- Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Mercer University, Atlanta, GA 30341, USA
| | | | | | | | | |
Collapse
|
40
|
Shastri PN, Ubale RV, D’Souza MJ. Implementation of mixture design for formulation of albumin containing enteric-coated spray-dried microparticles. Drug Dev Ind Pharm 2012; 39:164-75. [DOI: 10.3109/03639045.2012.664148] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|
41
|
Khafagy ES, Morishita M. Oral biodrug delivery using cell-penetrating peptide. Adv Drug Deliv Rev 2012; 64:531-9. [PMID: 22245080 DOI: 10.1016/j.addr.2011.12.014] [Citation(s) in RCA: 115] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2011] [Revised: 12/27/2011] [Accepted: 12/29/2011] [Indexed: 12/25/2022]
Abstract
During the past few decades, the novel biotherapeutic agents such as peptides and proteins have been contributed to the treatment of several diseases. However, their oral absorption is significantly limited due to their poor delivery through the intestinal mucosa. Therefore, the feasible approaches are needed for improving the oral bioavailability of biodrugs. Recently, cell-penetrating peptides (CPPs) such as HIV-1 Tat, penetratin and oligoarginine are considered as a useful tool for the intracellular delivery of therapeutic macromolecules. Hence, it was expected that the ability of CPPs may be applicable to enhance the absorption of biodrugs through intestinal epithelial membrane. CPPs are likely to become powerful tools for overcoming the low permeability of therapeutic peptides and proteins through the intestinal membrane, the major barrier to their oral delivery. Further advantage of this promising strategy is that this successful intestinal absorption could be achieved by more convenient methodology, coadministration of CPP with drugs via intermolecular interaction among them. Hereafter, the further establishment of delivery system based on CPPs is required to realize the development of the oral forms of therapeutic peptides and proteins. The aim here is to introduce our vision focusing on oral biodrug delivery by the use of CPPs as potential peptide carrier in order to provide new information in the design and development of new oral delivery systems for novel biotherapeutics.
Collapse
|
42
|
Pucciarelli S, Bonacucina G, Bernabucci F, Cespi M, Mencarelli G, De Fronzo GS, Natalini P, Palmieri GF. A Study on the Stability and Enzymatic Activity of Yeast Alcohol Dehydrogenase in Presence of the Self-Assembling Block Copolymer Poloxamer 407. Appl Biochem Biotechnol 2012; 167:298-313. [DOI: 10.1007/s12010-012-9692-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2011] [Accepted: 04/10/2012] [Indexed: 10/28/2022]
|
43
|
Brown CD, Stayton PS, Hoffman AS. Semi-interpenetrating network of poly(ethylene glycol) and poly(D, L-lactide) for the controlled delivery of protein drugs. JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION 2012; 16:189-201. [PMID: 15794485 DOI: 10.1163/1568562053115471] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
We have prepared a semi-interpenetrating network (IPN) of poly(ethylene glycol) dimethacrylate (PEGDMA) with entrapped poly(D,L-lactide) (PLA) using photochemical techniques. These IPNs were developed for the controlled delivery of protein drugs such as growth factors. The PEG component draws water into the network, forming a hydrogel within the PLA matrix, controlling and facilitating release of the protein drug, while the PLA component both strengthens the PEG hydrogel and enhances the degradation and elimination of the network after the protein drug is released. The rate and extent of swelling and the resultant protein release kinetics could be controlled by varying the PEG/PLA ratio and total PLA content. These IPNs were prepared using a biocompatible benzyl benzoate/benzyl alcohol solvent system that yields a uniform, fine dispersion of the protein throughout the PEG/PLA IPN matrix. IPNs composed of high molecular mass PLA and lower PEG/PLA ratios exhibited lower equilibrium swelling ratios. The release of bovine serum albumin (BSA), a model protein, from these IPNs was characterized by a large initial burst, regardless of the PEG/PLA ratio, due to the entrapment of residual solvent within the network. Microparticles of the PEG/PLA IPNs were also prepared using a modified Prolease strategy. Residual solvent removal was significantly enhanced using this process. The microparticles also exhibited a significant reduction in the initial burst release of protein. Mixtures of different compositions of PEG/PLA microparticles should be useful for the delivery of a variety of protein drugs with different release kinetics from any tissue-engineering matrix.
Collapse
Affiliation(s)
- Chad D Brown
- University of Washington, Department of Bioengineering, Box 352255, Seattle, WA 98195, USA
| | | | | |
Collapse
|
44
|
Jacobs S, Bunt CR, Wu Z, Lehr CM, Rupenthal ID. Characterization and evaluation of β-glucan formulations as injectable implants for protein and peptide delivery. Drug Dev Ind Pharm 2012; 38:1337-43. [DOI: 10.3109/03639045.2011.650646] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
45
|
Moebus K, Siepmann J, Bodmeier R. Novel preparation techniques for alginate-poloxamer microparticles controlling protein release on mucosal surfaces. Eur J Pharm Sci 2011; 45:358-66. [PMID: 22178531 DOI: 10.1016/j.ejps.2011.12.004] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2011] [Revised: 11/22/2011] [Accepted: 12/02/2011] [Indexed: 11/30/2022]
Abstract
The objective of this study was to develop novel preparation techniques for protein-loaded, controlled release alginate-poloxamer microparticles with a size range suitable for pulmonary administration. Bovine serum albumin (BSA)-loaded microparticles were prepared by spray-drying aqueous polymer-drug solutions, followed by cross-linking the particles in aqueous or ethanolic CaCl(2) or aqueous ZnSO(4) solutions. The microparticles were characterized with respect to their morphology (optical and scanning electron microscopy), particle size (laser light diffraction), calcium content (atom absorption spectroscopy), alginate content (complexation with 1,9-dimethyl methylene blue) and in vitro drug release (modified Franz diffusion cell). The spray-dried microparticles were spherical in shape with a size range of 4-6μm. Aqueous cross-linking led to a significant size increase (10-15μm), whereas ethanolic cross-linking did not. The substantial drug loss (∼50%) during aqueous CaCl(2) cross-linking could be avoided by using aqueous ZnSO(4) or ethanolic CaCl(2) solutions. Protein release from microparticles cross-linked with ethanolic CaCl(2) solutions was much faster than in the case of aqueous CaCl(2) solutions, probably due to the lower calcium content. The salt concentration and temperature of the cross-linking solutions also affected the composition of and drug release from the microparticles. Cross-linked alginate-poloxamer microparticles can be produced in a size range appropriate for deep lung delivery and with controlled protein release kinetics (time frame: hours to days) with these novel preparation techniques. The systems offer an interesting potential for the controlled mucosal delivery of protein drugs.
Collapse
Affiliation(s)
- Katrin Moebus
- College of Pharmacy, Freie Universität Berlin, Kelchstrasse 31, 12169 Berlin, Germany
| | | | | |
Collapse
|
46
|
Zadymova NM, Yampol’skaya GP, Poteshnova MV, Kulichikhin VG. Emulsion approach to production of polymer films used as carriers of lysozyme. COLLOID JOURNAL 2011. [DOI: 10.1134/s1061933x11050218] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
47
|
Albumin-coated porous hollow poly(lactic-co-glycolic acid) microparticles bound with palmityl-acylated exendin-4 as a long-acting inhalation delivery system for the treatment of diabetes. Pharm Res 2011; 28:2008-19. [PMID: 21472489 DOI: 10.1007/s11095-011-0427-4] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2011] [Accepted: 03/08/2011] [Indexed: 10/18/2022]
Abstract
PURPOSE To study the development of porous poly(lactic-co-glycolic acid) microparticles (PLGA MPs) coated initially with albumin and then with palmityl-acylated exendin-4 (Pal-Ex4) as an inhalation system for treating diabetes. METHODS Porous PLGA MPs were prepared by w/o/w double emulsification using hydroxypropyl-β-cyclodextrin and poly(ethylene-alt-maleic anhydride). Albumin was covalently attached to the MPs using EDC (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide); Pal-Ex4 was then bound on the albumin surface. Albumin-binding degree and aerosolization efficiency were investigated. Deposition of the MPs after insufflations into the lungs of ICR mice was observed by image monitoring, and pulmonary hypoglycemic efficacies were examined in db/db mice. Cytotoxicity and histopathology induced by MPs were examined in Calu-3 and A549 cells and in the lungs of db/db mice, respectively. RESULTS Albumin-coating and Pal-Ex4-binding to porous MP were performed with acceptable efficiencies. Pal-Ex4-bound albumin-coated MPs (Pal-Ex4/HSA-PLGA MP) were of high porosity and had appropriate aerodynamic sizes. Furthermore, this MP was efficiently deposited throughout mouse lungs, and exhibited a prolonged hypoglycemia and no significant lung tissue damage in db/db mice. CONCLUSION Pal-Ex4/HSA-PLGA MP demonstrated many meaningful pharmaceutical advantages for the treatment of diabetes, in terms of aerosolization efficiency, drug loading, sustained drug-release, and hypoglycemic duration in vivo.
Collapse
|
48
|
Soontornworajit B, Zhou J, Zhang Z, Wang Y. Aptamer-functionalized in situ injectable hydrogel for controlled protein release. Biomacromolecules 2011; 11:2724-30. [PMID: 20809645 DOI: 10.1021/bm100774t] [Citation(s) in RCA: 66] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Various in situ injectable hydrogels have been developed for protein delivery in treating human diseases. However, most hydrogels are highly permeable, which can lead to the rapid release of loaded proteins. The purpose of this study is to apply nucleic acid aptamers to functionalize an in situ injectable hydrogel model to control the release of proteins. The aptamers were studied using secondary structural predictions and binding analyses. The results showed that the structural predictions were different from the experimental measurements in numerous cases. The affinity of the aptamer was significantly affected by the mutations of the essential nucleotides, whereas it was not significantly affected by the variations of the nonessential nucleotides. The mutated aptamers were then used to functionalize the injectable hydrogel model. The results showed that the aptamer-functionalized hydrogel could prolong protein release. Moreover, the release rates could be controlled by adjusting the affinity of the aptamer.
Collapse
Affiliation(s)
- Boonchoy Soontornworajit
- Department of Chemical, Materials, and Biomolecular Engineering, University of Connecticut, Storrs, CT 06269-3222, USA
| | | | | | | |
Collapse
|
49
|
Newa M, Bhandari KH, Tang L, Kalvapalle R, Suresh M, Doschak MR. Antibody-mediated "universal" osteoclast targeting platform using calcitonin as a model drug. Pharm Res 2011; 28:1131-43. [PMID: 21301934 PMCID: PMC3073043 DOI: 10.1007/s11095-011-0376-y] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2010] [Accepted: 01/19/2011] [Indexed: 11/30/2022]
Abstract
Purpose To generate and characterize a specific monoclonal antibody (mAb) against recombinant human RANK receptor and to develop an antiresorptive strategy using this mAb as an osteoclast-targeting platform that selectively targets osteoclast cells whilst delivering an attached (i.e. chemically conjugated) active drug cargo. Methods Using hybridoma technology, we generated a specific monoclonal antibody (mAb) against recombinant human RANK receptor and characterized by SDS PAGE, ELISA, Western Blot and immunocytochemistry, then synthesized osteoclast-targeting bioconjugates of salmon calcitonin (sCT) using this antibody by generating thiol groups on mAb using 2-Iminothiolane and subsequently reacting them with sCT-PEG-MAL synthesised from sCT and NHS-PEG-MAL. To test the efficacy of the conjugate in vitro, osteoclasts were generated from precursor RAW 264.7 cells by dosing with the cytokines macrophage-colony-stimulating factor (M-CSF), and RANK Ligand (RANKL) and TRAP activity assay, Resorption Pit Assay, TRAP staining were performed. Cytotoxicity of the mAb-sCT conjugate was also evaluated in RAW 264.7 cells; sCT bioactivity and CTR binding potential were evaluated by in vitro intracellular cAMP stimulation assay in human T47D breast cancer cells. Results Generation of antibody against human RANK receptor was confirmed by SDS PAGE, ELISA and Western Blot. Immunocytochemistry confirmed the osteoclast targeting potential of the antibody. Successful conjugation of the antibody with sCT was confirmed by SDS PAGE and ELISA.Multinucleated osteoclast formation was confirmed by staining for tartrate-resistant acid phosphatase (TRAP). Conjugate functionality was confirmed by TRAP activity and Resorption Pit assay, showing the inhibitory effect on osteoclast differentiation. cAMP assay confirmed the retention of calcitonin bioactivity after conjugation. Conclusions Our strategy offers the potential for a “universal” osteoclast-targeting platform—one that targets the RANK receptor on osteoclast cells by simply altering the conjugated cargo in order to affect the specific regulation of osteoclast cells.
Collapse
Affiliation(s)
- Madhuri Newa
- Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta T6G2N8, Canada
| | | | | | | | | | | |
Collapse
|
50
|
Yadav SC, Kumari A, Yadav R. Development of peptide and protein nanotherapeutics by nanoencapsulation and nanobioconjugation. Peptides 2011; 32:173-87. [PMID: 20934475 DOI: 10.1016/j.peptides.2010.10.003] [Citation(s) in RCA: 76] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/15/2010] [Revised: 10/02/2010] [Accepted: 10/03/2010] [Indexed: 11/17/2022]
Abstract
The targeted delivery of therapeutic peptide by nanocarriers systems requires the knowledge of interactions of nanomaterials with the biological environment, peptide release, and stability of therapeutic peptides. Therapeutic application of nanoencapsulated peptides are increasing exponentially and >1000 peptides in nanoencapsulated form are in different clinical/trial phase. This review covers current scenario of therapeutic protein and peptides encapsulation on polymer to metallic nanocarriers including methods of protein encapsulation, peptide bioconjugation on nanoparticles, stability enhancement of encapsulated proteins and its biomedical applications.
Collapse
Affiliation(s)
- Subhash Chandra Yadav
- Nanobiology Lab, Biotechnology Division, Institute of Himalayan Bioresource Technology, Council of Scientific and Industrial Research, Palampur 176061 HP India.
| | | | | |
Collapse
|